Axsome Therapeutics (AXSM) Net Income towards Common Stockholders (2015 - 2026)
Axsome Therapeutics recorded quarterly Net Income towards Common Stockholders of -$64.5 million in Q1 2026, down 125.76% quarter-over-quarter from -$28.6 million in Q4 2025, and down 8.63% year-over-year from -$70.6 million in Q1 2025.
Axsome Therapeutics' Net Income towards Common Stockholders history runs 12 years deep, the most recent figure standing at -$64.5 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 8.63% year-over-year to -$64.5 million; the TTM figure through Mar 2026 stood at -$188.3 million (up 32.33% YoY), while the FY2025 annual figure was -$183.2 million, up 36.21% from the prior year.
- Net Income towards Common Stockholders came in at -$64.5 million for Q1 2026 at Axsome Therapeutics, down from -$28.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$11.2 million in Q1 2023 to a low of -$98.7 million in Q4 2023.
- A 5-year average of -$56.5 million and a median of -$61.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders soared 71.64% in 2023 and sank 508.27% in 2024, its largest moves.
- Axsome Therapeutics' Net Income towards Common Stockholders stood at -$61.2 million in 2022, then sank by 61.09% to -$98.7 million in 2023, then gained by 24.06% to -$74.9 million in 2024, then soared by 61.84% to -$28.6 million in 2025, then plunged by 125.76% to -$64.5 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$64.5 million, -$28.6 million, and -$47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -64.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.54 Mn |
| Dec 31, 2025 | -28.59 Mn |
| Sep 30, 2025 | -47.23 Mn |
| Jun 30, 2025 | -47.93 Mn |
| Mar 31, 2025 | -59.41 Mn |
| Dec 31, 2024 | -74.91 Mn |
| Sep 30, 2024 | -64.60 Mn |
| Jun 30, 2024 | -79.35 Mn |
| Mar 31, 2024 | -68.36 Mn |
| Dec 31, 2023 | -98.65 Mn |
| Sep 30, 2023 | -62.20 Mn |
| Jun 30, 2023 | -67.19 Mn |
| Mar 31, 2023 | -11.24 Mn |
| Dec 31, 2022 | -61.24 Mn |
| Sep 30, 2022 | -44.82 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -39.63 Mn |
| Dec 31, 2021 | -33.98 Mn |
| Sep 30, 2021 | -34.88 Mn |
| Jun 30, 2021 | -32.28 Mn |
| Mar 31, 2021 | -29.26 Mn |
| Dec 31, 2020 | -29.22 Mn |
| Sep 30, 2020 | -21.68 Mn |
| Jun 30, 2020 | -18.33 Mn |
| Mar 31, 2020 | -32.48 Mn |
| Dec 31, 2019 | -24.81 Mn |
| Sep 30, 2019 | -19.28 Mn |
| Jun 30, 2019 | -13.76 Mn |
| Mar 31, 2019 | -10.64 Mn |
| Dec 31, 2018 | 9.20 Mn |
| Sep 30, 2018 | -8.30 Mn |
| Jun 30, 2018 | -8.28 Mn |
| Mar 31, 2018 | -7.48 Mn |
| Dec 31, 2017 | 6.10 Mn |
| Sep 30, 2017 | 6.16 Mn |
| Jun 30, 2017 | 6.42 Mn |
| Mar 31, 2017 | 7.35 Mn |
| Dec 31, 2016 | 7.45 Mn |
| Sep 30, 2016 | 7.22 Mn |
| Jun 30, 2016 | 6.84 Mn |
| Mar 31, 2016 | 5.90 Mn |
| Dec 31, 2015 | 3.04 Mn |
| Sep 30, 2015 | 1.74 Mn |
| Jun 30, 2015 | 1.87 Mn |
| Mar 31, 2015 | 1.80 Mn |